Tallini G - Search Results

1

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Clifton-Bligh R, Tallini G, Holt EH, Sýkorová V. Xing M, et al. Among authors: tallini g. J Clin Oncol. 2015 Jan 1;33(1):42-50. doi: 10.1200/JCO.2014.56.8253. Epub 2014 Oct 20. J Clin Oncol. 2015. PMID: 25332244 Free PMC article.

2

Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease.

Tallini G, Ghossein RA, Emanuel J, Gill J, Kinder B, Dimich AB, Costa J, Robbins R, Burrow GN, Rosai J. Tallini G, et al. J Clin Oncol. 1998 Mar;16(3):1158-66. doi: 10.1200/JCO.1998.16.3.1158. J Clin Oncol. 1998. PMID: 9508203

3

RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.

Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A. Tallini G, et al. Clin Cancer Res. 1998 Feb;4(2):287-94. Clin Cancer Res. 1998. PMID: 9516913

4

RET oncogene activation in papillary thyroid carcinoma.

Tallini G, Asa SL. Tallini G, et al. Adv Anat Pathol. 2001 Nov;8(6):345-54. doi: 10.1097/00125480-200111000-00005. Adv Anat Pathol. 2001. PMID: 11707626 Review.

5

Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing.

Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, Tong BC, Tallini G, Udelsman R, Califano JA, Ladenson PW, Sidransky D. Xing M, et al. Among authors: tallini g. Cancer Res. 2003 May 1;63(9):2316-21. Cancer Res. 2003. PMID: 12727856

6

ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.

Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. Garcia-Rostan G, et al. Among authors: tallini g. J Clin Oncol. 2003 Sep 1;21(17):3226-35. doi: 10.1200/JCO.2003.10.130. J Clin Oncol. 2003. PMID: 12947056

7

Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis.

Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, Sidransky D. Xing M, et al. Among authors: tallini g. Cancer Res. 2004 Mar 1;64(5):1664-8. doi: 10.1158/0008-5472.can-03-3242. Cancer Res. 2004. PMID: 14996725

8

BRAF T1796A transversion mutation in various thyroid neoplasms.

Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D. Xing M, et al. Among authors: tallini g. J Clin Endocrinol Metab. 2004 Mar;89(3):1365-8. doi: 10.1210/jc.2003-031488. J Clin Endocrinol Metab. 2004. PMID: 15001635

9

Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker.

Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B. Wreesmann VB, et al. Among authors: tallini g. Cancer Res. 2004 Jun 1;64(11):3780-9. doi: 10.1158/0008-5472.CAN-03-1460. Cancer Res. 2004. PMID: 15172984

10

Tumor-specific changes in mtDNA content in human cancer.

Mambo E, Chatterjee A, Xing M, Tallini G, Haugen BR, Yeung SC, Sukumar S, Sidransky D. Mambo E, et al. Among authors: tallini g. Int J Cancer. 2005 Oct 10;116(6):920-4. doi: 10.1002/ijc.21110. Int J Cancer. 2005. PMID: 15856456

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

294 results

Search Page

Filters